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Heightened response to e-cigarettes
in COPD
To the Editor:
E-cigarettes are used as an alternative to cigarette smoking, and as nicotine replacement therapy, with
suggestions that they are markedly less harmful than cigarettes to the user. The confusion around the
safety of e-cigarettes stems from contradictory findings in which variations in experimental methodology
and the testing of different devices has not been accounted for. The harms associated with their use are
not well understood and this is commonly misconceived as meaning that they are a healthy alternative to
smoking. This misconception is further exacerbated by physicians and public health bodies which have
made recommendations without strong scientific evidence [1]. Multiple studies have concluded that
e-cigarette vapour exposure could lead to inflammation [2–5], emphysema [4] and a greater risk of
bacterial and viral infection [3]. The lack of a defined model for e-cigarette exposure for both in vitro
cellular and in vivo animal studies has led to contradictory findings between studies. Such differences can
be attributed to different devices (first versus fourth generation), vaporisation temperature, different
E-liquids or the concentration of e-cigarette vapour used. The confusion caused by contradictory findings
leaves consumers and clinicians to form their own opinions about e-cigarettes safety which may lead to
further public health issues in the future. Furthermore, no studies have compared responses in cells from
people with chronic obstructive pulmonary disease (COPD), a disease state where the use of e-cigarettes is
particularly attractive. However, COPD lung cells are known to be hyperresponsive to a range of
environmental stimuli including cigarette smoke and pollution, and therefore might also respond
differently to e-cigarette vapour.
The aim of this study was to evaluate dose–response relationships of e-cigarette stimulation of primary
airway smooth muscle cells (ASMCs) from people with and without COPD under realistic physiological
conditions. ASMCs were chosen for this study because of their contribution to pathological processes in
COPD. Not only is smooth muscle bulk increased in COPD airways, ASMCs have been shown to secrete
increased inflammatory mediators and chemokines compared with cells from smokers without COPD [6],
suggesting their response to inflammatory stimuli might contribute to lung inflammation and/or disease
progression in COPD. We have previously shown that ASMCs and airway fibroblasts from people with
COPD are hyperresponsive to cigarette smoke [6, 7], and hypothesised that they would also be
hyperresponsive to e-cigarettes. We also hypothesised that the increased toxic by-product formation seen
at higher vaporisation temperatures would result in greater cytotoxicity in ASMCs [8].
ASMCs from 22 patients were included in this study, of which nine had a diagnosis of COPD (forced
expiratory volume in 1 s (FEV1) <80%, FEV1/forced vital capacity <0.7). The non-COPD patients had
normal lung spirometry. E-cigarette vapour extract (EVE) was made by bubbling 20×5 s bursts of
E-vapour through 25 mL of DMEM supplemented with 0.1% Fetal Bovine Serum (FBS) ( JRH Biosciences,
Melbourne, Australia), 2.5 µg·mL−1 amphotericin B, 20 µg·mL−1 streptomycin and 20 U·mL−1 penicillin
(Invitrogen, Mount Waverly, Australia). CXCL8 release was measured using an ELISA kit (R&D systems,
Minneapolis, MN, USA) according to the manufacturer’s instructions. Cell viability was assessed by
measuring mitochondrial activity. 10 µL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) dye (Sigma Aldrich, Castle Hill, Australia) (0.005% w/v in sterile PBS) was added to each well,
followed by incubation for 6 h at 37°C in 5% carbon dioxide.
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To investigate if lung cells from people with COPD are hyperresponsive to e-cigarettes we stimulated COPD
and non-COPD cells with increasing concentrations of tobacco- and menthol-flavoured EVEs containing
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FIGURE 1 Primary human airway smooth muscle cells were stimulated with different concentrations of a, e)
18 mg·mL−1 nicotine tobacco-flavoured e-cigarette vapour extract (EVE), b, f) 0 mg·mL−1 nicotine tobacco-flavoured
EVE, c, g) 18 mg·mL−1 nicotine menthol-flavoured EVE and d, h) 0 mg·mL−1 nicotine menthol-flavoured EVE for
24 h. The control well contained 0.1% FBS DMEM. a–d) CXCL8 release production was measured in supernatant
using ELISA. Error bars represent ±SEM. Two-way ANOVA with Tukey’s post-test was used for statistical analysis,
significance is represented as *: p⩽0.05; **: p⩽0.01. e–h) Cytotoxicity was determined post-stimulation using an
MTT assay. Data are normalised to unstimulated cells and error bars represent ±SEM. Two-way ANOVA with
Tukey’s post-test was used for statistical analysis, significance is represented as *: p⩽0.05; ***: p⩽0.001. COPD:
chronic obstructive pulmonary disease; MTT: 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
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We selected these flavours as they proved to be more popular in smokers attempting to abstain from
smoking [9]. Both tobacco EVEs induced greater CXCL8 production in COPD cells compared with
non-COPD cells (figure 1a and b); however, this was not observed with the menthol EVEs (figure 1c and
d). Next, we investigated the effects of vaporisation temperature on toxicity, and found that menthol EVE
containing nicotine was more cytotoxic when generated at 60 W, with a trend towards increased toxicity
with menthol flavoured nicotine-free EVE (figure 1g and h). In contrast, tobacco-flavoured EVE had no
effect on cytotoxicity when generated at higher temperatures (figure 1 e and f).
Cytotoxicity and inflammation are aetiological in COPD as they both contribute to pathological processes
of the disease. Emphysema is caused by alveolar cell death and ineffective repair, resulting in an
enlargement of the alveolar spaces [10]. The cytotoxicity of cigarette smoke is well documented and
considered a contributing factor to disease progression. We have previously shown that cigarette smoke
extract is cytotoxic to primary human ASMCs using methodology similar to that used with EVEs here [6].
This method is representative of what happens in the lung tissue, as only soluble components of the
smoke or e-vapour will permeate through the epithelial layer to the underlying mesenchymal cells.
The power settings of the e-cigarette used were chosen according to the manufacturer’s guidelines and
users’ preferences. The maximum power recommended for this coil (60 W) was used, as users often prefer
to use their device at the high settings. Interestingly at the higher power setting, we found that that there
was a significant increase in cytotoxicity with 18 mg nicotine·mL−1 menthol e-vapour extract. Coils were
inspected before and after each extract generation and the tanks were refilled with e-liquid to confirm no
dry wicking was taking place.
Patients with COPD, or smokers, might switch to e-cigarettes as an alternative nicotine source, believing
that they are safer. All e-cigarette aerosols increased CXCL8 production in ASMCs irrespective of flavour
or nicotine concentration. This suggests that e-cigarettes would stimulate lung neutrophilic inflammation.
Furthermore, our data suggests that e-cigarette aerosol stimulates COPD cells in a similar manner to
cigarette smoke, resulting in an increased production of CXCL8 from COPD cells compared with
non-COPD cells.
Overall, our data suggests that COPD patients should avoid using e-cigarettes as a smoking cessation aid
as they have a similar ability to stimulate inflammation and lung damage as cigarette smoke, and thus
potentially accelerate their disease progression.
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